
Implanet was granted FDA clearance to market its Swingo anterior cervical cage.
The Swingo cage range features a portfolio of implant sizes with a design tailored to vertebral anatomy, supporting improved control of interbody fusion. The titanium implants, manufactured via 3D printing, can be used for all types of procedures, regardless of the chosen surgical approach. This clearance includes a dedicated next-generation instrumentation range designed to enhance patient safety while reducing surgical time.
Ludovic Lastennet, CEO of Implanet, said, “In the short term, combined with JSS (posterior fusion system), [the clearance] will enable us to offer a comprehensive range of implants dedicated to spinal fusion in the United States, our priority market. The potential synergies created by our expanded product portfolio fully support our strategy to strengthen our presence in the U.S.”
Source: Implanet
Implanet was granted FDA clearance to market its Swingo anterior cervical cage.
The Swingo cage range features a portfolio of implant sizes with a design tailored to vertebral anatomy, supporting improved control of interbody fusion. The titanium implants, manufactured via 3D printing, can be used for all types of procedures, regardless of the...
Implanet was granted FDA clearance to market its Swingo anterior cervical cage.
The Swingo cage range features a portfolio of implant sizes with a design tailored to vertebral anatomy, supporting improved control of interbody fusion. The titanium implants, manufactured via 3D printing, can be used for all types of procedures, regardless of the chosen surgical approach. This clearance includes a dedicated next-generation instrumentation range designed to enhance patient safety while reducing surgical time.
Ludovic Lastennet, CEO of Implanet, said, “In the short term, combined with JSS (posterior fusion system), [the clearance] will enable us to offer a comprehensive range of implants dedicated to spinal fusion in the United States, our priority market. The potential synergies created by our expanded product portfolio fully support our strategy to strengthen our presence in the U.S.”
Source: Implanet
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





